This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21 (PlGF)

This study has been terminated.
(The technique has been approved and validated)
Information provided by (Responsible Party):
OVO R & D Identifier:
First received: January 31, 2011
Last updated: July 24, 2015
Last verified: July 2015

This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other aneuploidies.

Aim of this prospective nonprofit study is to analyze the benefits of early onset pre eclampsia risk assessment in the 1st trimester (measuring biochemical markers [PIGF], blood pressure and Doppler ultrasound), and how the results can permit to modify or influence the course of the preeclampsia during the pregnancy. The investigators will also evaluate the potential use of the PIGF as a marker to improve the prenatal screening with the currently used nuchal translucency, serum Pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (fBhCG) parameters.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for Trisomy 21 and Other Aneuploidies

Resource links provided by NLM:

Further study details as provided by OVO R & D:

Primary Outcome Measures:
  • levels of Placental Protein 13 (PP13) , PIGF, PAPP-A, PIBF [ Time Frame: 6-13.6 wks gestation ]
    levels of PP13, PIGF, PAPP-A will de considered in association with Doppler ultrasound and standardised blood pressure measurements to see if they can be used as early risk markers in patients having a delivery before 34 weeks gestation

Biospecimen Retention:   Samples Without DNA

Enrollment: 370
Study Start Date: June 2012
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
study group
patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
women in 1st trimester of pregnancy coming to clinique OVO for prenatal screening

Inclusion Criteria:

  • Singleton pregnancy
  • Nulliparous pregnancy
  • Gestation age between 6.0-13.6 weeks by last menstrual period verified by ultrasound
  • Blood sample provided at gestational age 6.0-13.6 weeks
  • Informed Consent

Exclusion Criteria:

  • Multi-fetal pregnancy
  • Primiparous or multiparous pregnancy
  • Mental retardation or other mental disorders that impose doubts regarding the true patient's willingness to participate in the study
  • Gestation age below 6.0 or above 13.6 weeks by last menstrual period verified by ultrasound.
  • Lack of blood sample at the specified enrollment period
  • Known major fetal anomaly or fetal demise
  • Lack of demographic data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01387776

Canada, Quebec
OVO Prénatal
Montreal, Quebec, Canada, H4P2S4
Sponsors and Collaborators
Principal Investigator: Robert Hemmings, MD Clinique OVO
Study Director: Bernard Couturier, MD Clinique OVO
Study Chair: Dominique Berube, PhD Clinique OVO
  More Information

Responsible Party: OVO R & D Identifier: NCT01387776     History of Changes
Other Study ID Numbers: B-PRN-10-01
Study First Received: January 31, 2011
Last Updated: July 24, 2015

Additional relevant MeSH terms:
Down Syndrome
Hypertension, Pregnancy-Induced
Pregnancy Complications
Chromosome Aberrations
Pathologic Processes
Chromosome Duplication
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017